Soligenix names Marco Brughera to board
This article was originally published in Scrip
Executive Summary
Princeton, New Jersey-based Soligenix – a clinical stage biopharmaceutical company developing products to treat inflammatory diseases and biodefense medical countermeasures – has named Marco Maria Brughera to its board of directors. Dr Brughera is currently global head of the rare disease franchise for Sigma-tau, he is also a member of the company's board. Furthermore Dr Brughera is currently a member of the board for Italian biopharmaceutical company Gentium.